

Agreement Concerning Glaucoma and Ocular Hypertension

Treatment RESCULA® Eye Drops

November 2, 2007---R-Tech Ueno, Ltd. (Chiyoda-ku, Tokyo, Japan) and Santen Pharmaceutical Co., Ltd. (Osaka, Japan) today announced that the companies have reached a basic agreement to extend the exclusive marketing rights in Japan for RESCULA® Eye Drops (generic name: unoprostone isopropyl).

Under a sales contract signed for RESCULA® in July, 2004, R-Tech Ueno and Santen widely contributed to glaucoma patients and healthcare professionals through promotional activities by leveraging the both companies' advantages. Since the current contract is to expire in September, 2008, the companies were pursuing negotiations on the contract renewal and reached the basic agreement today. Accordingly, Santen continues to hold the exclusive marketing rights in Japan for RESCULA® beyond October 2008.

R-Tech Ueno's originally developed RESCULA® Eye Drops is the world's first Prostone-type ophthalmic solution for the treatment of glaucoma and ocular hypertension, and has been highly recognized among healthcare professionals since its launch in 1994. RESCULA® Eye Drops has an excellent safety profile with few topical or systemic side effects. Administered twice daily, the product shows stable reduction of elevated intraocular pressure. Its neuroprotective effect and mechanism of action increasing ocular blood flow help maintain the visual field of glaucoma (including normal tension glaucoma) and ocular hypertension patients for a long term.

Through this sales partnership, R-Tech Ueno and Santen hope to further contribute to improving the quality of life of glaucoma and ocular hypertension patients.

###